CD97与肿瘤关系的研究进展

摘要

CD97是黏附分子G蛋白偶联受体GPCRs家族中的核心成员，在免疫调节中发挥重要作用，与肿瘤的发生发展密切相关。CD97高表达与肿瘤患者不良预后相关，通过介导肿瘤细胞增殖、侵袭、转移以及重塑肿瘤免疫微环境等方式促进肿瘤进展。靶向CD97的抗体药物、CAR-T细胞疗法等诊疗策略已展现出潜在应用前景。

关键词

肿瘤 / CD97 / 预后 / 免疫微环境

参考文献

[1] YUAN Z N , LI Y P , ZHANG S F , et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments[J]. Mol Cancer, 2023, 22(1): 48. DOI: 10.1186/s12943—023—01744—8.

[2] ZHANG S S , XIAO X Y , YI Y L , et al. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets[J]. Signal Transduct Target Ther, 2024, 9(1): 149. DOI: 10.1038/s41392—024—01848—7.

[3] ZHANG C X , HUANG R Y—J , SHENG G , et al. Epithelial—mesenchymal transition[J]. Cell, 2025, 188(20): 5436-86. DOI: 10.1016/j.cell.2025.08.033.

[4] ALLGAYER H , MAHAPATRA S , MISHRA B , et al. Epithelial—to—mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025[J]. Mol Cancer, 2025, 24(1): 167. DOI: 10.1186/s12943—025—02338—2.

[5] 曹锋， 李嘉， 李非 . Notch信号通路与上皮—间质转化关系研究进展[J]. 中国现代普通外科进展， 2013， 16（2）： 138-41. DOI: 10.3969/j.issn.1009—9905.2013.02.016.

[6] HAMANN J , HARTMANN E , VAN LIER R A . Structure of the human CD97 gene: exon shuffling has generated a new type of seven—span transmembrane molecule related to the secretin receptor superfamily[J]. Genomics, 1996, 32(1): 144-7. DOI: 10.1006/geno.1996.0092.

[7] GRAY J X , HAINO M , ROTH M J , et al. CD97 is a processed, seven—transmembrane, heterodimeric receptor associated with inflammation[J]. J Immunol, 1996, 157(12): 5438-47. PMID: 8955192.

[8] MCKNIGHT A J , GORDON S . EGF—TM7: a novel subfamily of seven—transmembrane—region leukocyte cell—surface molecules[J]. Immunol Today, 1996, 17(6): 283-7. DOI: 10.1016/0167—5699(96)80546—9.

[9] KWAKKENBOS M J , KOP E N , STACEY M , et al. The EGF—TM7 family: a postgenomic view[J]. Immunogenetics, 2004, 55(10): 655-66. DOI: 10.1007/s00251—003—0625—2.

[10] SAFAEE M , CLARK A J , IVAN M E , et al. CD97 is a multifunctional leukocyte receptor with distinct roles in human cancers (Review)[J]. Int J Oncol, 2013, 43(5): 1343—50. DOI: 10.3892/ijo.2013.2075.

[11] EICHLER W . CD97 isoform expression in leukocytes[J]. J Leukoc Biol, 2000, 68(4): 561-7. PMID: 11037979.

[12] NIU M , XU S , YANG J , et al. Structural basis for CD97 recognition of the decay—accelerating factor CD55 suggests mechanosensitive activation of adhesion GPCRs[J]. J Biol Chem, 2021, 296: 100776. DOI: 10.1016/j.jbc.2021.100776. Epub 2021 May 14.

[13] HAMANN J , VOGEL B , VAN SCHIJNDEL G M , et al. The seven—span transmembrane receptor CD97 has a cellular ligand (CD55, DAF)[J]. J Exp Med, 1996, 184(3): 1185-9. DOI: 10.1084/jem.184.3.1185.

[14] HAMANN J , STORTELERS C , KISS—TOTH E , et al. Characterization of the CD55 (DAF)—binding site on the seven—span transmembrane receptor CD97[J]. Eur J Immunol, 1998, 28(5): 1701-7. DOI: 10.1002/(SICI)1521—4141(199805)28:05<1701::AID—IMMU1701>3.0.CO;2—2.

[15] MIKESCH J—H , SCHIER K , ROETGER A , et al. The expression and action of decay—accelerating factor (CD55) in human malignancies and cancer therapy[J]. Cell Oncol, 2006, 28(5—6): 223-32. DOI: 10.1155/2006/814816.

[16] SAUZAY C , VOUTETAKIS K , CHATZIIOANNOU A , et al. CD90/Thy—1, a Cancer—Associated Cell Surface Signaling Molecule[J]. Front Cell Dev Biol, 2019, 7: 66. DOI: 10.3389/fcell.2019.00066.

[17] RAVN—BOESS N , ROY N , HATTORI T , et al. The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability[J]. Cell Rep, 2023, 42(11): 113374. DOI: 10.1016/j.celrep.2023.113374.

[18] Aust G , Zheng L , Quaas M . To Detach, Migrate, Adhere, and Metastasize: CD97/ADGRE5 in Cancer[J]. Cells, 2022, 11(9): 1538. DOI: 10.3390/cells11091538.

[19] Mizuno N , Itoh H . Signal transduction mediated through adhesion—GPCRs[J]. Adv Exp Med Biol, 2010, 706: 157-66. DOI: 10.1007/978—1—4419—7913—1_14.

[20] YIN Y , XU X , TANG J , et al. CD97 Promotes Tumor Aggressiveness Through the Traditional G Protein—Coupled Receptor—Mediated Signaling in Hepatocellular Carcinoma[J]. Hepatology, 2018, 68(5): 1865-1878. DOI: 10.1002/hep.30068.

[21] LIN H—H . An Alternative Mode of GPCR Transactivation: Activation of GPCRs by Adhesion GPCRs[J]. Int J Mol Sci, 2025, 26(2): 552. DOI: 10.3390/ijms26020552.

[22] WARD Y , LAKE R , YIN J J , et al. LPA Receptor Heterodimerizes with CD97 to Amplify LPA—Initiated RHO—Dependent Signaling and Invasion in Prostate Cancer Cells[J]. Cancer Res, 2011, 71(23): 7301-11. DOI: 10.1158/0008—5472.CAN—11—2381.

[23] WARD Y , LAKE R , FARAJI F , et al. Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration[J]. Cell Rep, 2018, 23(3): 808-22. DOI: 10.1016/j.celrep.2018.03.092.

[24] WARD Y , LAKE R , MARTIN P L , et al. CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model[J]. Oncogene, 2013, 32(22): 2726-38. DOI: 10.1038/onc.2012.301.

[25] HILBIG D , DIETRICH N , WANDEL E , et al. The Interaction of CD97/ADGRE5 With β—Catenin in Adherens Junctions Is Lost During Colorectal Carcinogenesis[J]. Front Oncol, 2018, 8: 182. DOI: 10.3389/fonc.2018.00182.

[26] AUST G , EICHLER W , LAUE S , et al. CD97: a dedifferentiation marker in human thyroid carcinomas[J]. Cancer Res, 1997, 57(9): 1798-806. PMID: 9135025.

[27] MUSTAFA T , KLONISCH T , HOMBACH—KLONISCH S , et al. Expression of CD97 and CD55 in human medullary thyroid carcinomas[J]. Int J Oncol, 2004, 24(2): 285-94. PMID: 14719104.

[28] AUST G , STEINERT M , SCHüTZ A , et al. CD97, but not its closely related EGF—TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas[J]. Am J Clin Pathol, 2002, 118(5): 699-707. DOI: 10.1309/A6AB—VF3F—7M88—C0EJ.

[29] HAN S—L , XU C , WU X—L , et al. The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma[J]. Int J Colorectal Dis, 2010, 25(6): 695-702. DOI: 10.1007/s00384—010—0926—5.

[30] LIU D , TROJANOWICZ B , RADESTOCK Y , et al. Role of CD97 isoforms in gastric carcinoma[J]. Int J Oncol, 2010, 36(6): 1401—8. PMID: 20428763.

[31] LIU D , TROJANOWICZ B , YE L , et al. The Invasion and Metastasis Promotion Role of CD97 Small Isoform in Gastric Carcinoma[J]. Plos One, 2012, 7(6): e39989. DOI: 10.1371/journal.pone.0039989.

[32] WU J , LEI L , WANG S , et al. Immunohistochemical Expression and Prognostic Value of CD97 and Its Ligand CD55 in Primary Gallbladder Carcinoma[J]. J Biomed Biotechnol, 2012, 2012: 587672. DOI: 10.1155/2012/587672.

[33] HE Y , WANG W , XU L , et al. Immunohistochemical Expression and Prognostic Significance of CD97 and its Ligand DAF in Human Cervical Squamous Cell Carcinoma[J]. Int J Gynecol Pathol, 2015, 34(5): 473—9. DOI: 10.1097/PGP.0000000000000200.

[34] HE Z , WU H , JIAO Y , et al. Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer[J]. Oncol Lett, 2015, 9(2): 793-797. DOI: 10.3892/ol.2014.2751.

[35] LI C , LIU D—R , LI G—G , et al. CD97 promotes gastric cancer cell proliferation and invasion through exosome—mediated MAPK signaling pathway[J]. World J Gastroenterol, 2015, 21(20): 6215-28. DOI: 10.3748/wjg.v21.i20.6215.

[36] MENG Z—W , LIU M—C , HONG H—J , et al. Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma[J]. Tumour Biol, 2017, 39(3): 1010428317694319. DOI: 10.1177/1010428317694319.

[37] PARK G B , KIM D . MicroRNA—503—5p Inhibits the CD97—Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel—Resistant Ovarian Cancer Cells[J]. Neoplasia, 2019, 21(2): 206-215. DOI: 10.1016/j.neo.2018.12.005.

[38] 彭湃， 韩运涛， 邬攀， 等 . CD97和CD55在三阴性乳腺癌中的表达及其临床意义[J]. 中国现代医学杂志， 2019， 29（ 22）： 18-22. DOI: 10.3969/j.issn.1005—8982.2019.22.004.

[39] VAIKARI V P , YANG J , WU S , et al. CD97 expression is associated with poor overall survival in acute myeloid leukemia[J]. Exp Hematol, 2019, 75: 64-73.e4. DOI: 10.1016/j.exphem.2019.06.474.

[40] TANASE C , GHEORGHISAN—GALATEANU A—A , POPESCU I D , et al. CD36 and CD97 in Pancreatic Cancer versus Other Malignancies[J]. Int J Mol Sci, 2020, 21(16): 5656. DOI: 10.3390/ijms21165656.

[41] MUSTAFA T , ECKERT A , KLONISCH T , et al. Expression of the epidermal growth factor seven—transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(1): 108-19.

[42] HOANG V . Role of CD97 isoforms in gastric carcinoma[J]. Int J Oncol, 2010, 36(6): 1401—8. PMID: 20428763.

[43] STEINERT M , WOBUS M , BOLTZE C , et al. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues[J]. Am J Pathol, 2002, 161(5): 1657—67. DOI: 10.1016/S0002—9440(10)64443—4.

[44] GALLE J , SITTIG D , HANISCH I , et al. Individual cell—based models of tumor—environment interactions — Multiple effects of CD97 on tumor invasion[J]. Am J Pathol, 2006, 169(5): 1802-11. DOI: 10.2353/ajpath.2006.060006.

[45] TJONG W Y , LIN H H . The role of the RGD motif in CD97/ADGRE5—and EMR2/ADGRE2—modulated tumor angiogenesis[J]. BiochemBiophys Res Commun, 2019, 520(2): 243—9. DOI: 10.1016/j.bbrc.2019.09.113.

[46] KVOKACKOVA B , FEDR R , KUZILKOVA D , et al. Single—cell protein profiling defines cell populations associated with triple—negative breast cancer aggressiveness[J]. Mol Oncol, 2023, 17(6): 1024-1040. DOI: 10.1002/1878—0261.13365.

[47] ARCHANA C , HELEN L F , TIMOTHY VAN M , et al. Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness[J]. J Neurosurg, 2012, 116(4): 843-53. DOI: 10.3171/2011.11.JNS111455.

[48] MICHAEL S , ELAINA J W , SAKET J , et al. CD97 is associated with mitogenic pathway activation, metabolic reprogramming, and immune microenvironment changes in glioblastoma[J]. Sci Rep, 2022, 12(1): 1464. DOI: 10.1038/s41598—022—05259—y.

[49] GAëLLE M , NAINITA R , SOHINI C , et al. CD97 is a critical regulator of acute myeloid leukemia stem cell function[J]. J Exp Med, 2019, 216(10): 2362-2377. DOI: 10.1084/jem.20190598.

[50] NIKLAS R—B , NAINITA R , TAKAMITSU H , et al. The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability[J]. Cell Rep, 2023, 42(11): 113374. DOI: 10.1016/j.celrep.2023.113374.

[51] CHIDAMBARAM A , FILLMORE H L , VAN METER T E , et al. Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness Laboratory investigation[J]. J Neurosurg, 2012, 116(4): 843—53. DOI: 10.3171/2011.11.JNS111455.

[52] SAFAEE M M , WANG E J , JAIN S , et al. CD97 is associated with mitogenic pathway activation, metabolic reprogramming, and immune microenvironment changes in glioblastoma[J]. Sci Rep, 2022, 12(1): 1464. DOI: 10.1038/s41598—022—05259—y.

[53] MARTIN G H , ROY N , CHAKRABORTY S , et al. CD97 is a critical regulator of acute myeloid leukemia stem cell function[J]. J Exp Med, 2019, 216(10): 2362—77. DOI: 10.1084/jem.20190598.

[54] EICHBERG D G , SLEPAK T I , PASCOINI A L , et al. Genetic manipulation of adhesion GPCR CD97/ADGRE5 modulates invasion in patient—derived glioma stem cells[J]. J Neurooncol, 2021, 153(3): 383-91. DOI: 10.1007/s11060—021—03778—8.

[55] NIJMEIJER S , VISCHER H F , LEURS R . Adhesion GPCRs in immunology[J]. BiochemPharmacol, 2016, 114: 88-102. DOI: 10.1016/j.bcp.2016.04.013.

[56] HAMANN J , HSIAO C—C , LEE C S , et al. Adhesion GPCRs as Modulators of Immune Cell Function[J]. Handb Exp Pharmacol, 2016, 234: 329-350. DOI: 10.1007/978—3—319—41523—9_15.

[57] LIU D , DUAN L H , RODDA L B , et al. CD97 promotes spleen dendritic cell homeostasis through the mechanosensing of red blood cells[J]. Science, 2022, 375(6581): eabi5965. DOI: 10.1126/science.abi5965.

[58] SU Q M , LI L , LI X K , et al. CD97 serves as a novel biomarker of immune cell infiltration in hepatocellular carcinoma[J]. World J Surg Oncol, 2022, 20(1): 382. DOI: 10.1186/s12957—022—02829—2.

[59] SHEN H , JIN M , GU S , et al. CD97 Is Decreased in Preeclamptic Placentas and Promotes Human Trophoblast Invasion Through PI3K/Akt/mTOR Signaling Pathway[J]. Reprod Sci, 2020, 27(8): 1553-61. DOI: 10.1007/s43032—020—00183—w.

[60] SAFAEE M M , WANG E J , JAIN S , et al. CD97 is associated with mitogenic pathway activation, metabolic reprogramming, and immune microenvironment changes in glioblastoma[J]. Sci Rep, 2022, 12(1): 1464. DOI: 10.1038/s41598—022—05259—y.

[61] ZHANG H , YUE X , CHEN Z , et al. Define cancer—associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials[J]. Mol Cancer, 2023, 22(1): 159. DOI: 10.1186/s12943—023—01860—5.

[62] WANG T , TIAN L , HAINO M , et al. Improved antibacterial host defense and altered peripheral granulocyte homeostasis in mice lacking the adhesion class G protein receptor CD97[J]. Infect Immun, 2007, 75(3): 1144-53. DOI: 10.1128/IAI.00869—06.

[63] SPENDLOVE I , SUTAVANI R . The role of CD97 in regulating adaptive T—cell responses[J]. Adv Exp Med Biol, 2010, 706: 138-48. DOI: 10.1007/978—1—4419—7913—1_12.

[64] CAPASSO M , DURRANT L G , STACEY M , et al. Costimulation via CD55 on human CD4+ T cells mediated by CD97[J]. J Immunol, 2006, 177(2): 1070—7. DOI: 10.4049/jimmunol.177.2.1070.

[65] ABBOTT R J , SPENDLOVE I , ROVERSI P , et al. Structural and functional characterization of a novel T cell receptor co—regulatory protein complex, CD97—CD55[J]. J Biol Chem, 2007, 282(30): 22023-32. DOI: 10.1074/jbc.M702588200.

[66] ZHOU S , LIN W , JIN X , et al. CD97 maintains tumorigenicity of glioblastoma stem cells via mTORC2 signaling and is targeted by CAR Th9 cells[J]. Cell Rep Med, 2024, 5(12): 101844. DOI: 10.1016/j.xcrm.2024.101844.

[67] LIU D , WU J , ZHU H , et al. Treatment of microvascular invasion in hepatocellular carcinoma with drug—loaded nanocomposite platform under synergistic effect of magnetic field/near—infrared light[J]. J Biomed Mater Res B Appl Biomater, 2022, 110(3): 712-24. DOI: 10.1002/jbm.b.34950.

[68] WANG N , QIAN Y , XIA R , et al. Structural basis of CD97 activation and G—protein[J]. Cell Chem Biol, 2023, 30(11): 1343-1353. DOI: 10.1016/j.chembiol.2023.08.003.

[69] KRUMM B E , ROTH B L . CryoEM structures of adhesion in GPCR CD97: Filling in some of the gaps[J]. Cell Chem Biol, 2023, 30(11): 1327—9. DOI: 10.1016/j.chembiol.2023.10.014.

[70] SHANG K , HUANG D , LIU J , et al. CD97—directed CAR—T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models[J]. Cell Rep Med, 2025, 6(6): 102148. DOI: 10.1016/j.xcrm.2025.102148.

[71] HATTORI T , WANG M , CORRADO A D , et al. Engineering antibody—drug conjugates targeting an adhesion GPCR, CD97[J]. Proc Natl Acad Sci U S A, 2025, 122(40): e2516627122. DOI: 10.1073/pnas.2516627122.

基金资助

国家自然科学基金项目(82070288)

湖北省自然科学基金联合项目(2026AFC1277)

普外科国家重点建设专科项目(XGZX202403)

孝感市科技局课题(XGKJ2024010038)